Although these experimental results explain the effectiveness of RTK inhibition by small molecules, only two have reached clinical stage for example Erlotinib, an EGFR inhibitor and Sorafenib, a VEGFR inhibitor for improving liver fibrosis. Here, EGFR is linked to Hepatic fibrosis.